Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - Midatech Pharma US Inc. | dara_8k.htm |
Exhibit 16.1
19 July 2012
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01(a) of Form 8-K dated 19 July 2012, of DARA BioSciences, Inc. and are in agreement with the statements contained in the second, third, fourth and fifth paragraphs. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young LLP
cc: PCAOB Letter File
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561